JP7837963B2 - 糖尿病を処置するための修飾型インスリンおよびグルコキナーゼ核酸 - Google Patents

糖尿病を処置するための修飾型インスリンおよびグルコキナーゼ核酸

Info

Publication number
JP7837963B2
JP7837963B2 JP2023524498A JP2023524498A JP7837963B2 JP 7837963 B2 JP7837963 B2 JP 7837963B2 JP 2023524498 A JP2023524498 A JP 2023524498A JP 2023524498 A JP2023524498 A JP 2023524498A JP 7837963 B2 JP7837963 B2 JP 7837963B2
Authority
JP
Japan
Prior art keywords
seq
vector
sequence
nucleic acid
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023524498A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022006551A5 (https=
JP2023542241A5 (https=
JP2023542241A (ja
Inventor
ナチ グプタ，
ウェイラン シェン，
マルティネス， ミケル ガルシア
センサーノ， ヴェロニカ ヒメネス
トゥーベルト， マリア ファティマ ボッシュ
Original Assignee
クリヤ セラピューティクス， インコーポレイテッド
ウニヴェルシタット・アウトノマ・デ・バルセロナ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クリヤ セラピューティクス， インコーポレイテッド, ウニヴェルシタット・アウトノマ・デ・バルセロナ filed Critical クリヤ セラピューティクス， インコーポレイテッド
Publication of JP2023542241A publication Critical patent/JP2023542241A/ja
Publication of JPWO2022006551A5 publication Critical patent/JPWO2022006551A5/ja
Publication of JP2023542241A5 publication Critical patent/JP2023542241A5/ja
Priority to JP2025256145A priority Critical patent/JP2026034616A/ja
Application granted granted Critical
Publication of JP7837963B2 publication Critical patent/JP7837963B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01002—Glucokinase (2.7.1.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023524498A 2020-07-03 2021-07-02 糖尿病を処置するための修飾型インスリンおよびグルコキナーゼ核酸 Active JP7837963B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025256145A JP2026034616A (ja) 2020-07-03 2025-12-16 糖尿病を処置するための修飾型インスリンおよびグルコキナーゼ核酸

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063047965P 2020-07-03 2020-07-03
US63/047,965 2020-07-03
US202063054162P 2020-07-20 2020-07-20
US63/054,162 2020-07-20
US202063067264P 2020-08-18 2020-08-18
US63/067,264 2020-08-18
US202163141918P 2021-01-26 2021-01-26
US63/141,918 2021-01-26
US202163188778P 2021-05-14 2021-05-14
US63/188,778 2021-05-14
PCT/US2021/040366 WO2022006551A2 (en) 2020-07-03 2021-07-02 Modified insulin and glucokinase nucleic acids for treating diabetes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025256145A Division JP2026034616A (ja) 2020-07-03 2025-12-16 糖尿病を処置するための修飾型インスリンおよびグルコキナーゼ核酸

Publications (4)

Publication Number Publication Date
JP2023542241A JP2023542241A (ja) 2023-10-05
JPWO2022006551A5 JPWO2022006551A5 (https=) 2024-07-10
JP2023542241A5 JP2023542241A5 (https=) 2024-07-10
JP7837963B2 true JP7837963B2 (ja) 2026-03-31

Family

ID=79317842

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023524498A Active JP7837963B2 (ja) 2020-07-03 2021-07-02 糖尿病を処置するための修飾型インスリンおよびグルコキナーゼ核酸
JP2025256145A Pending JP2026034616A (ja) 2020-07-03 2025-12-16 糖尿病を処置するための修飾型インスリンおよびグルコキナーゼ核酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025256145A Pending JP2026034616A (ja) 2020-07-03 2025-12-16 糖尿病を処置するための修飾型インスリンおよびグルコキナーゼ核酸

Country Status (10)

Country Link
US (1) US20240279300A1 (https=)
EP (1) EP4176060A4 (https=)
JP (2) JP7837963B2 (https=)
KR (1) KR20230087436A (https=)
CN (1) CN116234904A (https=)
AU (1) AU2021300450A1 (https=)
CA (1) CA3174156A1 (https=)
IL (1) IL299545A (https=)
MX (1) MX2023000099A (https=)
WO (1) WO2022006551A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250288693A1 (en) * 2022-04-29 2025-09-18 Kriya Therapeutics, Inc. Insulin and glucokinase gene therapy compositions and its use for treating diabetes
AU2024370040A1 (en) * 2023-11-01 2026-04-23 Kriya Therapeutics, Inc. Aav mediated insulin and glucokinase gene therapy for treating diabetes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012007458A1 (en) 2010-07-12 2012-01-19 Universidad Autónoma De Barcelona Gene therapy composition for use in diabetes treatment
WO2016110518A1 (en) 2015-01-07 2016-07-14 Universitat Autònoma De Barcelona Single-vector gene construct comprising insulin and glucokinase genes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1836047B (zh) * 2003-06-17 2010-12-22 赛姆生物系统遗传公司 在植物中生产胰岛素的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012007458A1 (en) 2010-07-12 2012-01-19 Universidad Autónoma De Barcelona Gene therapy composition for use in diabetes treatment
WO2016110518A1 (en) 2015-01-07 2016-07-14 Universitat Autònoma De Barcelona Single-vector gene construct comprising insulin and glucokinase genes

Also Published As

Publication number Publication date
CA3174156A1 (en) 2022-01-06
IL299545A (en) 2023-02-01
AU2021300450A1 (en) 2023-03-02
EP4176060A4 (en) 2024-08-07
KR20230087436A (ko) 2023-06-16
CN116234904A (zh) 2023-06-06
WO2022006551A2 (en) 2022-01-06
MX2023000099A (es) 2023-04-20
JP2026034616A (ja) 2026-02-27
EP4176060A2 (en) 2023-05-10
WO2022006551A3 (en) 2022-02-03
US20240279300A1 (en) 2024-08-22
JP2023542241A (ja) 2023-10-05

Similar Documents

Publication Publication Date Title
JP7184894B2 (ja) アデノ随伴ウイルス変異キャプシドおよび血管新生の阻害のための使用
US11344608B2 (en) Factor IX gene therapy
EP3242945B1 (en) Single-vector gene construct comprising insulin and glucokinase genes
US20240091383A1 (en) Synergistic effect of smn1 and mir-23a in treating spinal muscular atrophy
JP2026034616A (ja) 糖尿病を処置するための修飾型インスリンおよびグルコキナーゼ核酸
JP2014534245A (ja) 効率の高いトランスジーン送達のためのウイルスベクター
CN116440292A (zh) Danon病和其它自噬障碍的治疗方法
CN116685329B (zh) 核酸构建体及其用于治疗脊髓性肌肉萎缩症的用途
EP3390623B1 (en) Wilson's disease gene therapy
WO2026001133A1 (zh) 腺相关病毒突变体及其应用
WO2024020444A2 (en) Muscle-specific regulatory cassettes
US20250288693A1 (en) Insulin and glucokinase gene therapy compositions and its use for treating diabetes
KR20230003557A (ko) 스펙트린 융합 도메인을 갖는 소형화 디스트로핀 및 그의 용도
RU2839898C2 (ru) Синергетическое действие SMN1 и miR-23a при лечении спинальной мышечной атрофии
WO2022221462A1 (en) Vector constructs for delivery of nucleic acids encoding therapeutic vlcad or mcad and methods of using the same
WO2025096954A1 (en) Aav mediated insulin and glucokinase gene therapy for treating diabetes
JP2026507523A (ja) 遺伝子療法のためのｂｃｌ２関連アタノゲン３（ｂａｇ３）をコードする核酸
OA21365A (en) Synergistic effect of SMN1 and MIR-23A in treating spinal muscular atrophy.
HK40092769A (zh) 用於治疗眼部疾病的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240702

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260318

R150 Certificate of patent or registration of utility model

Ref document number: 7837963

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150